Secondary stroke prevention in people with atrial fibrillation: treatments and trials

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Atrial fibrillation is a common arrhythmia and a primary cause of ischemic stroke.
• Understanding atrial fibrillation burden and timing relative to stroke is crucial for recurrence risk.
• Secondary prevention aims to mitigate recurrent ischemic stroke in patients with atrial fibrillation.

Purpose of the Study:

• To review current secondary prevention strategies for patients with atrial fibrillation and stroke.
• To highlight optimal timing for direct oral anticoagulant therapy initiation post-stroke.
• To discuss emerging therapies and unmet needs in secondary stroke prevention.

Main Methods:

• Review of randomized controlled trials on anticoagulant therapy timing.
• Analysis of emerging treatments like rhythm control and left atrial appendage occlusion.
• Examination of secondary prevention in patients with stroke despite anticoagulation and those with prior intracerebral hemorrhage.

Main Results:

• Early initiation of direct oral anticoagulants (within 48h for minor/moderate, 4-5 days for large strokes) appears safe and reduces early recurrence.
• Novel therapies including rhythm control, left atrial appendage occlusion, and factor XI inhibitors show promise for further risk reduction.
• Secondary prevention in patients with atrial fibrillation experiencing stroke despite anticoagulation is an unmet need, with ongoing research.

Conclusions:

• Optimal timing of anticoagulation initiation is key for secondary stroke prevention in atrial fibrillation.
• Emerging therapies offer new avenues for reducing stroke risk in this population.
• Further research is needed to address secondary prevention challenges, particularly in patients with prior intracerebral hemorrhage or those experiencing stroke despite anticoagulation.